Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 3

1(14.3%)

Phase 1

1(14.3%)

7Total

N/A(5)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04032119Phase 3Completed

RCT of Gastric ESD With or Without Epineprhine Added Solution

Role: collaborator

NCT04497376Not ApplicableCompleted

Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation

Role: collaborator

NCT04347330Not ApplicableUnknown

Cardiovascular Risk Reduction in Atrial Fibrillation Trial

Role: collaborator

NCT01261234Not ApplicableCompleted

Carotid Artery Stenting With Cilostazol Addition for Restenosis

Role: collaborator

NCT01278628Phase 1Completed

SUMCO Metabolic Syndrome Project

Role: lead

NCT02158624Not ApplicableUnknown

Ranibizumab Treatment for Age-Related Macular Degeneretion

Role: collaborator

NCT00916019Not ApplicableCompleted

Investigation of the Effects of Exercise on Gene Expression

Role: lead

All 7 trials loaded